微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2017, Vol. 9 ›› Issue (5): 387-390.doi: 10.3969/j.issn.1674-5671.2017.05.11

• 临床研究 • 上一篇    下一篇

#br# 雷替曲塞单药二线治疗老年晚期结直肠癌的疗效分析

  

  1. 广西中医药大学附属瑞康医院肿瘤二科
  • 出版日期:2017-10-25 发布日期:2017-11-02
  • 通讯作者: 侯恩存 E-mail：houec2008@sina.com

Clinical observation of raltitrexed as second-line chemotherapy for advanced colorectal cancer in elderly patients

  • Online:2017-10-25 Published:2017-11-02

PDF (PC)

421

赞

摘要：

目的 观察单药雷替曲塞在老年晚期结直肠癌二线治疗中的疗效、安全性和影响预后的因素。方法 回顾性分析2012年1月至2016年12月在我院确诊并使用单药雷替曲塞二线化疗的老年晚期结直肠癌患者的资料。结果 符合入组条件患者27例，有效率为3.7%（1/27），疾病控制率为48.1%（13/27），中位无进展生存期为3.8个月，中位总生存期为10.0个月，毒副反应以Ⅰ~Ⅱ级为主，主要为粒细胞减少、贫血、转氨酶异常、疲乏及恶心呕吐。多因素分析显示PS评分状态及有无肝转移是影响患者预后的独立因素。结论 雷替曲塞单药二线治疗老年晚期结直肠癌安全有效，值得临床推广应用。

关键词: 结直肠肿瘤, 晚期, 老年人, 雷替曲塞, 疗效

Abstract:

Objective To investigate the efficacy and toxicity of raltitrexed as second-line chemotherapy for advanced colorectal cancer in elderly patients，and to discuss the correlation between clinical features and survival. Methods We retrospectively analyzed elderly advanced colorectal cancer patients who were treated with raltitrexed as second-line chemotherapy in Ruikang Affiliated Hospital of Guangxi Traditional Medical University from 1st January 2012 to 31st December 2016. Results A total of 27 patients was included. The response rate was 3.7%，the disease control rate was 48.15%，the median progression free survival was 3.8 months，the median overall survival was 10 months. The main adverse reactions included granulopenia，anemia，transaminase elevation，nausea/vomiting and exhausted，most of which were grade Ⅰ-Ⅱ. Multiple factor analysis showed PS status and liver metastasis were the main independent predictors on overall survival． Conclusion Raltitrexed as the second line chemotherapy showed satisfactory efficacy and safety to treat the elderly patients with advanced colorectal cancer.

Key words: Colorectal neoplasms, Advanced stage, Elder, Raltitrexed , Efficacy